Surgery As Needed for Oesophageal Cancer - 2

Launched by BAS P. L. WIJNHOVEN · May 10, 2021

Keywords

ClinConnect Summary

The SANO-2 study is a clinical trial designed to explore the best approach for treating patients with esophageal cancer after they receive initial treatment with chemotherapy and radiation. This study focuses on whether patients can safely be monitored without immediate surgery after their initial treatment, which may be less invasive and more comfortable for them.

To participate in this trial, patients must be at least 18 years old and have a specific type of esophageal cancer that has been confirmed through testing. They should also have recently received a particular treatment called neoadjuvant chemoradiotherapy, which is a combination of chemotherapy and radiation therapy given before surgery. During the study, participants will be closely monitored to evaluate their health and any changes in their cancer. It’s important to note that not everyone will qualify; for example, those who have had different initial treatments or have difficulty understanding the study will not be eligible. The goal is to find out the best ways to treat esophageal cancer while considering the patients' overall well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Operable patients who are planned to undergo or who recently underwent neoadjuvant chemoradiotherapy according to CROSS followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophago-gastric junction
• • Age ≥18
• • Written, voluntary, informed consent.
• Exclusion Criteria:
• • Non-FDG-avid tumour at baseline PET-CT scan
• • Initial treatment with endoscopic resection
• • Patients who underwent of who are planned to undergo definitive chemoradiotherapy
• • Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent.